A Shibli-Rahhal1, B Paturi. 1. Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA, amal-rahhal@uiowa.edu.
Abstract
UNLABELLED: Although 25 hydroxyvitamin D (25OHD) and parathyroid hormone (PTH) levels are inversely related, less than half of the patients with a low vitamin D level have an elevated PTH, and, in most of these patients, the PTH does not immediately normalize with correction of the vitamin D. INTRODUCTION: Despite the inverse relationship between 25OHD and PTH, patients with vitamin D deficiency seen in clinical practice do not always have an elevated PTH, and, in those with secondary hyperparathyroidism, the PTH does not always normalize with correction of vitamin D deficiency. We examined variations in PTH concentrations in patients with low 25OHD and studied changes in the PTH concentration with restoration of vitamin D sufficiency. METHODS: This was a retrospective cohort study of patients with a 25OHD < 30 ng/mL and a concomitant PTH measurement seen at the Metabolic Bone Disease Clinic at a tertiary care center between July 1, 2007 and May 31, 2011. Patients with conditions associated with alterations in PTH were excluded. RESULTS: The study population consisted of 104 patients. The mean age was 55.5 years, and 83 % were female. The 25OHD and PTH were negatively correlated, but only 30 % of patients with a 25OHD < 30 ng/mL and 40 % of those with a 25OHD < 20 ng/mL had an elevated PTH. As the 25OHD increased to 30 ng/mL or higher, the PTH decreased significantly in the group of patients who had an elevated PTH at baseline, but only 44 % reached a normal PTH. Of patients with a normal PTH at baseline, 59 % experienced a drop in their PTH while the PTH remained unchanged or increased in 41 %. CONCLUSIONS: PTH has a limited role in defining vitamin D status in individual patients and in guiding vitamin D therapy in clinical practice.
UNLABELLED: Although 25 hydroxyvitamin D (25OHD) and parathyroid hormone (PTH) levels are inversely related, less than half of the patients with a low vitamin D level have an elevated PTH, and, in most of these patients, the PTH does not immediately normalize with correction of the vitamin D. INTRODUCTION: Despite the inverse relationship between 25OHD and PTH, patients with vitamin D deficiency seen in clinical practice do not always have an elevated PTH, and, in those with secondary hyperparathyroidism, the PTH does not always normalize with correction of vitamin D deficiency. We examined variations in PTH concentrations in patients with low 25OHD and studied changes in the PTH concentration with restoration of vitamin D sufficiency. METHODS: This was a retrospective cohort study of patients with a 25OHD < 30 ng/mL and a concomitant PTH measurement seen at the Metabolic Bone Disease Clinic at a tertiary care center between July 1, 2007 and May 31, 2011. Patients with conditions associated with alterations in PTH were excluded. RESULTS: The study population consisted of 104 patients. The mean age was 55.5 years, and 83 % were female. The 25OHD and PTH were negatively correlated, but only 30 % of patients with a 25OHD < 30 ng/mL and 40 % of those with a 25OHD < 20 ng/mL had an elevated PTH. As the 25OHD increased to 30 ng/mL or higher, the PTH decreased significantly in the group of patients who had an elevated PTH at baseline, but only 44 % reached a normal PTH. Of patients with a normal PTH at baseline, 59 % experienced a drop in their PTH while the PTH remained unchanged or increased in 41 %. CONCLUSIONS:PTH has a limited role in defining vitamin D status in individual patients and in guiding vitamin D therapy in clinical practice.
Authors: Ravinder J Singh; Robert L Taylor; G Satyanarayana Reddy; Stefan K G Grebe Journal: J Clin Endocrinol Metab Date: 2006-05-23 Impact factor: 5.958
Authors: Michael F Holick; Ethel S Siris; Neil Binkley; Mary K Beard; Aliya Khan; Jennifer T Katzer; Richard A Petruschke; Erluo Chen; Anne E de Papp Journal: J Clin Endocrinol Metab Date: 2005-03-29 Impact factor: 5.958
Authors: I González-Molero; S Morcillo; S Valdés; V Pérez-Valero; P Botas; E Delgado; D Hernández; G Olveira; G Rojo; C Gutierrez-Repiso; E Rubio-Martín; E Menéndez; F Soriguer Journal: Eur J Clin Nutr Date: 2010-12-22 Impact factor: 4.016
Authors: Natalia O Kuchuk; Saskia M F Pluijm; Natasja M van Schoor; Caspar W N Looman; Johannes H Smit; Paul Lips Journal: J Clin Endocrinol Metab Date: 2009-01-21 Impact factor: 5.958
Authors: Marlena C Kruger; Yoke Mun Chan; Lee Ting Lau; Chin Chin Lau; Yit Siew Chin; Barbara Kuhn-Sherlock; Joanne M Todd; Linda M Schollum Journal: Eur J Nutr Date: 2017-10-03 Impact factor: 5.614
Authors: Helen Titmarsh; Scott Kilpatrick; Jennifer Sinclair; Alisdair Boag; Elizabeth F Bode; Stephanie M Lalor; Donna Gaylor; Jacqueline Berry; Nicholas X Bommer; Danielle Gunn-Moore; Nikki Reed; Ian Handel; Richard J Mellanby Journal: PLoS One Date: 2015-05-13 Impact factor: 3.240
Authors: Ahmed A Madar; Kirsten V Knutsen; Lars C Stene; Mette Brekke; Per Lagerløv; Haakon E Meyer; Helen M Macdonald Journal: Bone Rep Date: 2015-05-21